Laurent Galibert Appointed Head of Inflammation Business Unit

Addex First Half 2008 Financial Results Monday, July 28

Addex Starts Phase I ADX10059 Interaction Study

Disclosure of Shareholdings in Accordance with Stock Market Rules

Addex Starts ADX10059 Phase I Formulation Selection Study

Addex Appoints Laurent Massuyeau as Head of Business Development

Addex Shareholders Elect Ray Hill to Board of Directors at the 2008 Annual General Meeting

Addex Pharmaceuticals R&D Day on April 24

Mark Epping-Jordan, Chief Scientific Officer, Resigns

Disclosure of Shareholdings in Accordance with Stock Market Rules